Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?

Nature Reviews Neurology

Volumn 11, Issue 8, 2015, Pages 429-430

  Desjardins, Annick ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; IRINOTECAN; PLACEBO; TEMOZOLOMIDE; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DACARBAZINE; MONOCLONAL ANTIBODY;

BRAIN EDEMA; BRAIN INJURY; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG INDICATION; DRUG MECHANISM; DRUG USE; GLIOBLASTOMA; HUMAN; IMMUNOTHERAPY; INOPERABLE CANCER; KIDNEY CANCER; LUNG CANCER; NOTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DRUG COST; ECONOMICS; FEMALE; MALE; QUALITY OF LIFE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; DRUG COSTS; FEMALE; GLIOBLASTOMA; HUMANS; MALE; QUALITY OF LIFE;

EID: 84938969959     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2015.127     Document Type: Note

References (10)

1. Taphoorn, M. J. et al. Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma. J. Clin. Oncol. 33, 2166-2175 (2015).
2. Kovic, B. & Xie, F. Economic evaluation of bevacizumab for the first-line treatment of newly diagnosed glioblastoma multiforme. J. Clin. Oncol. http://dx.doi.org/10.1200/ JCO.2014.59.7245.
3. Jain, R. K., Duda, D. G., Clark, J. W. & Loeffler, J. S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3, 24-40 (2006).
4. Godard, S. et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res. 63, 6613-6625 (2003).
5. Stefanik, D. F. et al. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J. Neurooncol. 55, 91-100 (2001).
6. Friedman, H. S. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4733-4740 (2009).
7. Kreisl, T. N. et al. Phase II trial of single-Agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27, 740-745 (2009).
8. Chinot, O. L. et al. Bevacizumab plus radiotherapy-Temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709-722 (2014).
9. Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699-708 (2014).
10. Lou, E. et al. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Med. 2, 185-195 (2013).